VistaGen Therapeutics

Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company headquartered in South San Francisco, California, leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively activate peripheral receptors on human nasal chemosensory neurons and are designed to rapidly trigger olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Vistagen's lead programs target highly prevalent conditions including social anxiety disorder (SAD), major depressive disorder (MDD), and vasomotor symptoms associated with menopause. The company's lead candidate, fasedienol nasal spray, is in Phase 3 development for the acute treatment of social anxiety disorder under the PALISADE clinical program.